Borealis appoints IMCD as Bormed™ healthcare portfolio distributor

Photo: The distribution agreement applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices. Ⓒ Borealis
The distribution agreement will take effect as of October 1, 2021. The new agreement applies to Bormed™ portfolio of innovative polyolefin grades for healthcare. Complementary Borealis and IMCD product portfolios will enable even more choice in polymers.
Borealis announces that it has selected IMCD, a global leader in the distribution of specialty chemicals and ingredients, as its new European distributor of its dedicated grade range of Bormed™ polyolefins for healthcare.
The distribution agreement covers most of Europe (with the exception of Switzerland and the South-Eastern countries) and takes effect as of 1 October 2021. It applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices.
As a distributor with a strong presence in medical and healthcare applications, IMCD is the ideal partner for Borealis customers in Europe thanks to its broad technical expertise and dedicated medical application team. The extensive IMCD polymers range complements the Borealis Bormed portfolio, opening a range of new possibilities.
IMCD was selected from a broad field of potential distributors following a rigorous screening process.
“We are pleased to have found in IMCD a partner sharing the core Bormed values of service, commitment and conformance,” said John Webster, Borealis Head of Sales Advanced Products.
“What also unites us is our dedication to providing best-in-class service to all of our healthcare customers, both direct and indirect, by way of more intensive and efficient value chain collaboration. We are confident that this new agreement will significantly boost our presence in this increasingly important sector.”
In line with its commitment to service as the foundation of successful industry co-operation, Borealis and IMCD will together ensure a seamless distribution transition for their customers, who can continue to count on security of supply as well as the ready assistance of experienced technical and sales teams.
Olivier Champault, Director of IMCD Business Group Advanced Materials said: “We are delighted to be selected as the new partner for Borealis in their healthcare business. This partnership is completely aligned with our strategy to further expand and strengthen our presence in the medical and healthcare segment in Europe.
With our dedicated experts in medical and healthcare applications, our well-established distribution network, and our board product offering, we are fully committed to accelerate growth and to support our customers in their developments and innovations.”

Related News
-
News A Day in the Life of Oncology Start-Up Co-Founder & CEO
This Women's month we are highlighting stories of women in the pharma industry (building on what we do every month to support women), so for the Day in the Life of we are speaking to Sharon Cunningham who is the Co-founder and CEO of Shorla On... -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News A Day in the Life of a Head of Market Insights in med devices
The latest interview in the Day in the Life of Series is with Alper Hulusi, Head of Market Insights for ClariMed. Hulusi also works to try to get to know people, this time from the other side of pharma – the people that will be using the the... -
News CPHI Podcast Series: Packaging expert perspectives at Pharmapack 2025
This month's podcast episode sounds a little different, covering the latest event in Paris – Pharmapack 2025. Digital Editor Lucy Chard speaks to several experts direct from the floor of the show, bringing you right in on the action.&nbs... -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News The 2025 Pharmapack Awards: recognising innovation and patient centricity
This year in Paris the Pharmapack Awards recognised the achievements across categories in the industry, aswell as including some new categories to highlight exceptional work and people. -
News Pharmapack 2025: From the Floor in Paris
Pharmpack gears up for another week in Paris at the Porte De Versailles. The two-day show taking place on the 22–23 January, will cover contract packaging, device innovation, and sustainability among other topics. -
News Visibility, Integration, and Opportunity with CPOs: A Pharmapack Interview
At Pharmapack 2025 in Paris the informative content tracks this year will feature a Contract Packaging track. A critically important topic for those working in the field, which speaker Alexander Schäfer from Sharp Services discusses in the fo...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance